Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/COR-22-063113/2022 was isolated from a human in May 2022, in Memphis, Tennessee, USA. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV-19/USA/COR-22-063113/2022 is assigned lineage BA.5 using the Phylogenetic Assignment of Named Global Outbreak lineages (PANGO) tool. It was labeled as an Omicron variant by the World Health Organization (WHO).

Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The pre-inactivation titer was determined from an infectious aliquot. Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.
Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability and performance characteristics should be determined by your laboratory for each intended usage. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.

For BSL-2 or BSL-3 compliant labs only / -20° C.
Product Insert.pdf